We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+33.46%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$247M
AUM Growth
-$117M
Cap. Flow
-$139M
Cap. Flow %
-56.36%
Top 10 Hldgs %
58.38%
Holding
95
New
54
Increased
7
Reduced
11
Closed
22

Top Buys

Rank Stock Value
1
WST icon
West Pharmaceutical
WST
+$23M
2
MRK icon
Merck
MRK
+$13M
3
AXSM icon
Axsome Therapeutics
AXSM
+$12M
4
APLS
Apellis Pharmaceuticals
APLS
+$11.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.7M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$24.2M
2
ARGX icon
argenx
ARGX
+$23.5M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$20.9M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$20.7M
5
LLY icon
Eli Lilly
LLY
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 90.81%
2 Real Estate 0.3%
3 Industrials 0.1%
4 Financials 0.1%
5 Energy 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
26
TG Therapeutics
TGTX
$7.07B
$3.41M 1.38%
+288,462
New +$2.09M
KZR
27
DELISTED
Kezar Life Sciences
KZR
$3.33M 1.35%
47,354
-23,619
-33% -$1.75M
BEAM icon
28
Beam Therapeutics
BEAM
$2.67B
$3.21M 1.3%
82,018
+28,264
+53% +$1.27M
RVNC
29
CALL
DELISTED
Revance Therapeutics, Inc.
RVNC
$3.07M 1.24%
+166,300
New +$3.8M
RXDX
30
CALL
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$2.83M 1.14%
+25,700
New +$1.67M
PTGX icon
31
CALL
Protagonist Therapeutics
PTGX
$8.51B
$2.18M 0.88%
199,500
– –
GH icon
32
CALL
Guardant Health
GH
$21.3B
$1.7M 0.69%
+62,600
New +$2.86M
BMRN icon
33
CALL
BioMarin Pharmaceuticals
BMRN
$11.7B
$1.36M 0.55%
+13,100
New +$1.23M
APLS
34
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$889K 0.36%
+17,200
New +$912K
ARGX icon
35
argenx
ARGX
$52B
$492K 0.2%
1,299
-62,853
-98% -$23.5M
AHRT
36
AH Realty Trust
AHRT
$527M
$168K 0.07%
+14,573
New +$168K
AM icon
37
Antero Midstream
AM
$10.4B
$164K 0.07%
+15,153
New +$161K
WU icon
38
Western Union
WU
$2.28B
$153K 0.06%
+11,096
New +$153K
PDM
39
Piedmont Realty Trust
PDM
$1.24B
$148K 0.06%
+16,088
New +$159K
HPP
40
Hudson Pacific Properties
HPP
$786M
$111K 0.04%
+1,632
New +$121K
AIV
41
Aimco
AIV
$387M
$101K 0.04%
+14,169
New +$108K
SFL icon
42
SFL Corp
SFL
$1.65B
$99K 0.04%
+10,702
New +$104K
MTW icon
43
Manitowoc
MTW
$514M
$95K 0.04%
+10,358
New +$94.5K
FEMY icon
44
Femasys
FEMY
$8.97M
$92K 0.04%
5,137
-193
-4% -$4.5K
SAFE
45
Safehold
SAFE
$1.16B
$89K 0.04%
+1,858
New +$89.5K
LPRO
46
DELISTED
Open Lending Corp
LPRO
$85K 0.03%
+12,661
New +$89.1K
GPRO icon
47
GoPro
GPRO
$131M
$80K 0.03%
+16,062
New +$84.3K
LL
48
DELISTED
LL Flooring Holdings, Inc.
LL
$74K 0.03%
+13,185
New +$92.4K
UNIT
49
Uniti Group
UNIT
$2.34B
$69K 0.03%
+12,491
New +$85.8K
TCS
50
DELISTED
THE CONTAINER STORE GROUP, INC.
TCS
$65K 0.03%
+1,002
New +$72.5K
1
2
3 4

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return

Tri Locum Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Tri Locum Partners held 95 positions worth $247M, down 32% from $364M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Tri Locum Partners withdrew a net $139M in Q4 2022, closing 22 positions and reducing 11 holdings. Its most notable exit was Biogen, an estimated $24.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 93% a quarter earlier, followed by Real Estate and Industrials.

Against the trend, Tri Locum Partners opened a new position in West Pharmaceutical worth $22.8M.

  • Tri Locum Partners's largest Q4 2022 buy was West Pharmaceutical: 97,084 shares worth $22.8M.
  • Tri Locum Partners added most to Sarepta Therapeutics in Q4 2022, an estimated $2.81M increase.
  • Tri Locum Partners's biggest Q4 2022 reduction was argenx, cutting an estimated $23.5M.
  • Tri Locum Partners fully exited Biogen in Q4 2022, selling an estimated $24.2M.
  • Tri Locum Partners's ten largest holdings make up 58% of its $247M portfolio in Q4 2022.
  • Tri Locum Partners opened 54 new positions and closed 22 in Q4 2022.
  • Tri Locum Partners's portfolio value fell 32% quarter-over-quarter to $247M.

Based on Tri Locum Partners's 13F filing for Q4 2022, filed 14 Feb 2023.